Until then the peptide problem is growing and changing every day and it likely will remain one of the biggest challenges for retailers, anti-doping authorities, government regulators, the medical community, and consumer safety advocates to address over the next decade or more
It is particularly beneficial for individuals struggling with autoimmune conditions, IBD, or systemic inflammation
In clinical use, the most commonly reported side effects are: Mild injection site redness or swelling (resolves within hours) Occasional lightheadedness following injection (less common, position-dependent) Temporary nausea with oral administration in some patients Who should not use BPC-157: Patients with active cancer or a history of cancer should discuss BPC-157 carefully with their oncologist before use angiogenic peptides theoretically could support tumor vascularity, though no evidence of this has been demonstrated in animals
Pentadecapeptide BPC 157 and its effects on hypertension and heart damage
This question has two answers